Form D · Biotechnology
EUPRAXIA PHARMACEUTICALS INC.
Victoria, A1 · CIK 0001581178
Offering snapshot reported Nov 8, 2024 · SEC filing
- Reported sold
- $1.89M Offering amount: $1.89M
- Investors reported
- 6 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 31, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 8, 2024 | Initial | $1,894,413 | No comparison | 6 | SEC filing |
| Aug 22, 2023 | Initial | $128,394 | No comparison | 3 | SEC filing |
| Apr 18, 2016 | Initial | $37,951 | No comparison | 1 | SEC filing |
| Sep 16, 2013 | Initial | $24,277 | No comparison | 1 | SEC filing |
| Jul 11, 2013 | Initial | $23,782 | No comparison | 1 | SEC filing |
| Jul 11, 2013 | Initial | $376,848 | No comparison | 14 | SEC filing |
| Jul 11, 2013 | Initial | $5,066 | No comparison | 1 | SEC filing |
| Jul 11, 2013 | Initial | $10,139 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-528976
U.S. dollar amounts are based on the Bank of Canada average rate of exchange reported on October 31, 2024, which was CDN$1.3916=US$1.00.
Source: Form D, filed Nov 8, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Brennan | Executive |
| Bruce Cousins | Executive |
| Joseph Freedman | Director |
| Paul Geyer | Director |
| Richard Glickman | Director |
| James Helliwell | Director, Executive |
| Mark Kowalski | Executive |
| Amanda Malone | Executive |
| John Montalbano | Director |
| Simon Pimstone | Director |
| Rahul Sarugaser | Executive |
| David Stadnyk | Director |
| George Tsafalas | Executive |
| Michael Wilmink | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
201 2067 Cadboro Bay Rd.
Victoria, A1, V8R 5G4
Victoria, A1, V8R 5G4